Papers matching “complete remission” in Acute Myeloid Leukemia Research 66
Not finding it? Sign in to also search OpenAlex live.
-
Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG
Romy E. van Weelderen, Kim Klein, Christine J. Harrison, Hester A. de Groot‐Kruseman, Jonas Abrahamsson, Nira Arad‐Cohen, +24 more
0citations -
Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Features in First Complete Remission As per the International Consensus Classification (ICC) 2022: A Study from the ALWP of the EBMT2024 Transplantation and Cellular Therapy article Medicine Acute Myeloid Leukemia Research Open access
Arnon Nagler, Myriam Labopin, Jurjen Versluis, Jaime Sanz, Tobias Gedde‐Dahl, David Burns, +11 more
1citations -
Trends in Allogeneic Transplantation for Favorable Risk Acute Myeloid Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT2024 Transplantation and Cellular Therapy article Medicine Acute Myeloid Leukemia Research Open access
Arnon Nagler, Myriam Labopin, Urpu Salmenniemi, Depei Wu, Didier Blaise, Alessandro Rambaldi, +15 more
0citations -
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva‐Maria Wagner‐Drouet, Lutz Peter Müller, Christoph Schmid, +62 more
53citations -
Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
Christoph Röllig, Björn Steffen, Nael Alakel, Regina Herbst, Richard Noppeney, Maher Hanoun, +32 more
5citations -
Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT
Ann‐Kristin Schmälter, Myriam Labopin, Jurjen Versluis, Maria Pilar Gallego Hernanz, Matthias Eder, Peter A. von dem Borne, +12 more
1citations -
Remission Induction Versus Immediate Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed or Poor Responsive Acute Myeloid Leukemia (ASAP): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva Wagner-Drouet, Lutz Peter Müller, Christoph Schmid, +29 more
5citations -
Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner Drouet, Lutz Peter Mueller, Christoph Schmid, +30 more
0citations -
Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
Inga Hund, Maria Elena Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, +13 more
0citations -
Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML - the SAL/AMLCG Vincent Trial
Leo Ruhnke, Christoph Schliemann, Lars R. Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, +26 more
2citations